


Glenmark Pharmaceuticals Limited

Statement of audited financial results for the quarter and year ended 31 March, 2018

(Rs.In Million)

	Particulars [Refer notes below]	Standalone (Ind AS)				
		Quarter ended 31/03/2018 (Audited) [refer note 10]	Quarter ended 31/12/2017 (Unaudited)	Quarter ended 31/03/2017 (Audited) [refer note 10]	Year ended 31/03/2018 (Audited)	Year ended 31/03/2017 (Audited)
I	Revenue from operations					
	(a) Net sales	15,063.27	14,592.46	19,385.61	60,960.52	76,948.30
	(b) Other operating income	1,614.18	973.03	1,265.26	3,358.32	4,006.70
	Total revenue from operations	16,677.45	15,565.49	20,650.87	64,318.84	80,955.00
II	Other income	442.98	372.32	(502.49)	1,804.22	1,482.39
III	Total income (I + II)	17,120.43	15,937.81	20,148.38	66,123.06	82,437.39
IV	Expenses					
	(a) Cost of materials consumed	5,312.54	5,224.70	5,478.75	20,385.67	22,420.13
	(b) Purchase of stock-in-trade	632.69	891.95	560.33	2,881.77	2,669.96
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	347.33	(304.49)	1.02	518.47	(835.17)
	(d) Employee benefits expense	2,323.30	2,553.98	2,211.26	10,219.21	9,144.71
	(e) Finance costs	507.22	469.99	497.21	1,908.98	1,526.02
	(f) Depreciation and amortisation expense	298.18	295.53	273.17	1,182.04	1,049.32
	(g) Other expenses	4,758.48	4,531.39	5,678.52	16,838.67	18,568.95
	Total expenses (IV)	14,179.74	13,663.05	14,700.26	53,934.81	54,543.92
V	Profit/(loss) before exceptional items and tax (III - IV)	2,940.69	2,274.76	5,448.12	12,188.25	27,893.47
VI	Exceptional items [Refer note 14]	-	-	2,364.51	-	2,364.51
VII	Profit/(loss) before tax (V - VI)	2,940.69	2,274.76	3,083.61	12,188.25	25,528.96
VIII	Tax expense :					
	Current tax	733.52	489.59	1,462.71	2,706.77	6,040.24
	Deferred tax	(7.95)	(155.99)	(1,949.67)	(661.99)	(1,917.36)
IX	Profit/(loss) for the period (VII - VIII)	2,215.12	1,941.16	3,570.57	10,143.47	21,406.08
X	Other comprehensive income					
	A (i) Items that will not be reclassified to profit or loss	36.41	(11.92)	35.90	(10.20)	(34.40)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	(12.60)	4.12	(12.20)	3.53	11.70
	B (i) Items that will be reclassified to profit or loss	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-
XI	Total comprehensive income	2,238.93	1,933.36	3,594.27	10,136.80	21,383.38
XII	Total comprehensive income attributable to:					
	- Non-controlling interests	-	-	-	-	-
	- Owners of the Company	2,238.93	1,933.36	3,594.27	10,136.80	21,383.38
XIII	Earning per share (EPS)					
	(of Re 1/- each) (not annualised)					
	Basic EPS (in Rupees)	7.85	6.88	12.65	35.95	75.86
	Diluted EPS (in Rupees)	7.85	6.88	12.65	35.94	75.84



Glenmark Pharmaceuticals Ltd.

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai - 400 099, India

Tel: 4018 9999 F: 91 22 4018 9986 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com